金币
UID287463
帖子
主题
积分6484
注册时间2017-2-14
最后登录1970-1-1
听众
性别保密
|
发表于 2026-1-12 08:08:20
|
显示全部楼层
不需要,不建议在PPQ做上下限的原因: 如果将独立参数都设定在“失效边缘”进行验证,这些变量之间的影响可能会相互抵消,从而无法真正证明工艺的稳健性。见制药工艺验证手册:
“Concepts such as “worst case” and “processing range validation” resulted in pro-tocols that prescribe independent parameters to be set on “edge of failure.” Running processes with all parameters set at a low level, or conversely set at a high level, proves nothing because it is not known if the effect of extremes of the various parameters can cancel each other. For example, running a tablet press at the minimum weight at minimum speed may be acceptable, where minimum weight at mod-erate or high speed may be unacceptable. The Guidance expects this type of limit justifcation to be performed with factorial experimentation (DOE) within R&D during Stage 1.12 Formerly, process validation (now PPQ) was generally accepted to mean three batches run with parameters set at typical setpoint values. This may still be the case for a generic or OTC, where a process has been acquired with no accompanying development data. In this case, process his-tory with similar products may support minimal develop-ment trials in determining independent process parameters for equipment settings. For new drugs, it is assumed that equipment-focused development and qualifcation studies for the specifc are completed prior to PPQ. The results of these studies for facility and process are confrmed under formal protocol and are called design qualifcation (DQ)” |
|